Singapore markets open in 7 hours 25 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
223.45-6.61 (-2.87%)
As of 01:35PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close230.06
Open230.06
Bid222.93 x 100
Ask223.76 x 100
Day's range223.20 - 230.06
52-week range189.44 - 281.12
Volume502,622
Avg. volume1,114,534
Market cap32.534B
Beta (5Y monthly)-0.04
PE ratio (TTM)27.90
EPS (TTM)8.01
Earnings date23 Jul 2024 - 29 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est279.64
  • Zacks

    Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

  • Insider Monkey

    Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth

    ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed the Russell 1000 Value Index in the first quarter. On an absolute basis, the strategy has gained 9 out of eleven sectors it invested in during […]

  • GlobeNewswire

    Biogen Completes Acquisition of Human Immunology Biosciences

    CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indicat